|
Cardiovascular Vulnerability to Particulate Exposure Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Cardiovascular Vulnerability to Particulate Exposure conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Cardiovascular Vulnerability to Particulate Exposure Clinical research trials and Cardiovascular Vulnerability to Particulate Exposure health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Cardiovascular Vulnerability to Particulate Exposure. Cardiovascular Vulnerability to Particulate Exposure Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Cardiovascular Vulnerability to Particulate Exposure clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Cardiovascular Vulnerability to Particulate Exposure condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Cardiovascular Vulnerability to Particulate Exposure  Cardiovascular Vulnerability to Particulate Exposure
Cardiovascular Vulnerability to Particulate Exposure
For Condition: Lung Disease,Heart Disease
Status: Recruiting
Sponsor(s): National Institute of Environmental Health Sciences (NIEHS) ,
Synopsis: This project is part of a program project directed toward assessing cardiac effects of particulate and other ambient air pollutants. In this project active elderly adults living in the communities of Boston and Steubenville have attended 12 weekly sessions including approximately 40 minutes of Holter monitoring, blood pressure, and oximetry evaluation before, during, and after outdoor exercise. To investigate the relation of air pollution to cardiac and pulmonary rehabilitation, a second portion of this study involves abstraction of blood pressure and symptom data and downloading of available repeated measures telemetry data in two populations. These populations include: 1) 200 outpatients attending 8 to 36 repeated weekly exercise training sessions in a major hospital cardiac rehabilitation unit.
Details: Approximately 60 subjects have participated fully in Boston and Steubenville in the repeated 40 minute measurement of continuous EKG (Holter), blood pressure, and oximetry. In Steubenville we have also measured exhaled nitrogen oxide, an index of pulmonary inflammation. The exposure monitoring has included outdoor particle mass of PM2.5, outdoor gaseous pollutants, and indoor home and personal monitoring to evaluate the indoor contribution of pollution to health effects.
Eligibility:
Study Type: Observational, Natural History, Longitudinal, Defined Population, Prospective Study
Minimum Age/Maximum Age: 50 Years/90 Years
Genders: Both
Protocol Entry Criteria: Participants are 50 to 90 years of age, but almost all are 60 and older. They have been enrolled as volunteers from communities in Mission Park, Boston, and Steubenville. Inclusion criteria includes the ability to walk on level ground. Exclusion criteria includes unstable anginal, and baseline EKG patterns such as left bundle branch block that would make difficult the detection of repolarization abnormalities. Participants live at or near the study center which was located in an office or apartment in the apartment building of the majority of the participants.
Total Enrollment: 200
Location and Contact Information:
Overall Study Official:
DianeGold, Study Director, Harvard School of Public Health
Brigham and Women's Hospital *Recruiting*
Boston, Massachusetts, 02115
United States
Recruiting Diane Gold 617-525-2738
Additional Information:
Study ID Numbers: 9825-CP-003;
Study Start Date: September 1998
Record last reviewed: April 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00013949
Other Lung Disease Studies:
1. Evaluation of Patients with Known or Suspected Heart Disease
2. Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial
3. Cardiovascular Vulnerability to Particulate Exposure
4. Evaluation of Patients with Heart Disease Not Eligible for Research Protocols
5. Deferoxamine for the Treatment of Hemochromatosis
Related Studies:
Other Lung Disease Clinical Trials
Other Massachusetts Clinical Trials
Other Boston Clinical Trials
Cardiovascular Vulnerability to Particulate Exposure
|
|
|
|
|
|
|
|
